Notice2024-25162
Government Owned Inventions Available for Licensing/Collaboration: Using Artificial Intelligence To Diagnose Uveitis
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 30, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Eye Institute seeks (NEI), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the licensing and collaboration opportunity for the inventions listed below, which are owned by an agency of the U.S. Government and are available for licensing/ collaboration in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 210 (Wednesday, October 30, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 210 (Wednesday, October 30, 2024)]
[Notices]
[Page 86343]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-25162]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions Available for Licensing/
Collaboration: Using Artificial Intelligence To Diagnose Uveitis
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Eye Institute seeks (NEI), an institute of the
National Institutes of Health (NIH), Department of Health and Human
Services (HHS), is giving notice of the licensing and collaboration
opportunity for the inventions listed below, which are owned by an
agency of the U.S. Government and are available for licensing/
collaboration in the U.S. to achieve expeditious commercialization of
results of federally-funded research and development.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing/
collaboration opportunity should be directed to: Hiba Alsaffar, Ph.D.,
Technology Transfer Manager, NCI, Technology Transfer Center, Email:
<a href="/cdn-cgi/l/email-protection#fd95949f9cd39c918e9c9b9b9c8fbd939495d39a928b"><span class="__cf_email__" data-cfemail="9ff7f6fdfeb1fef3ecfef9f9feeddff1f6f7b1f8f0e9">[email protected]</span></a> or Phone: 240-276-7489.
SUPPLEMENTARY INFORMATION: Uveitis is caused by inflammation in the eye
that can cause pain and reduce vision. The rate of uveitis in the
United States is 1 in every 200 people with eye-related irritation.
Permanent symptoms such as vision loss can occur if untreated.
Therefore, early detection is crucial. In certain uveitis cases,
fluorescein angiography (FA) is essential for the diagnosis and
management due to its ability to display retinal vascular leakage
(RVL). Although proven to be critical in diagnosing and assessing
severity, FA is invasive and side effects have been reported.
Additionally, the procedure is time-consuming and imposes economic
burdens to patients, physicians and payors. Scientists at the NEI have
developed a deep learning tool to non-invasively detect RVL using
ultrawide-field color fundus photos. This algorithm identifies fundus
images with and without RVL with high accuracy (79%) and sensitivity
(85%). Compared to the current gold standard of assessing RVL
(clinician interpretation), this deep learning tool provides an
improved method of detecting RVL for patients with uveitis.
This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part
404.
NIH Reference Number: E-005-2023-0.
Potential Commercial Applications:
<bullet> Diagnostic tool to predict uveitis.
<bullet> Add-on to current color fundus imaging modalities.
Competitive Advantages:
<bullet> Greater accuracy and sensitivity versus current gold
standard to assess RVL (clinician assessment).
<bullet> Deep learning tool to assess RVL.
<bullet> Deep learning to assess ultrawide-field color fundus
images and assess RVL.
Publication: Young LH, et al. Automated Detection of Vascular
Leakage in Fluorescein Angiography--A Proof of Concept. (PMID
35877095).
Patent Status: US Provisional Application 65/599,446 filed on
November 15, 2023.
Development Stage: Prototype.
Therapeutic Area(s): Eye, Ear, Nose, Throat.
Dated: October 24, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2024-25162 Filed 10-29-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 30, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.